RNS Announcements

Director/PDMR Shareholdings

30 May 2025

ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, is pleased to announce that Directors and PDMRs of the Company have acquired a total of 549,082 ordinary shares of 0.05p each in the Company ("Ordinary Shares").

Following these acquisitions, the Directors of the Company are interested in Ordinary Shares as follows:

Name

Number of Ordinary Shares acquired

Shareholding

%

Adam Reynolds

50,000

192,857

0.06

Steen Andersen

125,450

125,450

0.04

Stephen O'Hara

-

6,131,450

3.88

Marco Caspani

-

-

-

Frederik Bruhn-Petersen*

-

3,000,000

1.90

 

*Frederik Bruhn-Petersen is also interested in the 33,160,000 Ordinary Shares, representing 20.97% of the Company's issued share capital, held by Holdingselskabet of 29. Juni 2010 Aps.

Further information about the acquisitions of Ordinary Shares by the Directors and PDMRs is set out in the table below.

 

For further information, please contact:

ProBiotix Health plc

https://probiotixhealth-ir.com

Steen Andersen, Chief Executive Officer

Miles Nolan, Investor Relations

[email protected] 



Peterhouse Capital Limited

Aquis Corporate Adviser and Broker

 

 

Mark Anwyl

Duncan Vasey

Tel: 020 7220 9793

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Adam Reynolds

Steen Andersen

Mark Collingbourne

Michael Litichevski

Mads Brandt

2

Reason for the notification

a)

Position/status

Chairman

Chief Executive

 

Chief Finance Officer

Vice President, Sales

Head of Supply Chain

b)

Initial notification /Amendment

 

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer, or auction monitor

a)

Name

ProBiotix Health plc

b)

LEI

98450048683CF0388C30

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

 

Ordinary Shares of 0.05p each

 

ISIN: GB00BLNBFR86

b)

Nature of the transactions

Acquisition of Ordinary Shares

c)

Price(s) and volume(s)

50,000 Ordinary Shares at 7.88p per share

125,450

Ordinary Shares at 7.83p per share

 

108,907

Ordinary Shares at 7.25p per share

75,780 Ordinary Shares at 7.25p per share

188,945

Ordinary Shares at 7.83p per share

d)

Aggregated information

- Aggregated volume

- Price

 

n/a - single transaction

 

n/a - single transaction

 

n/a - single transaction

 

n/a - single transaction

 

n/a - single transaction

e)

Date of the transactions

29 May 2025

f)

Place of the transactions

Aquis Growth Market

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

back to RNS & Investor News